TY - STD TI - Huang Z: Baidu, China’s version of Google, is “evil,” a growing number of users say. In Quartz. http://qz.com/674030/baidu-chinas-version-of-google-is-evil-a-growing-number-of-users-say/. Accessed 10 Jan 2017. UR - http://qz.com/674030/baidu-chinas-version-of-google-is-evil-a-growing-number-of-users-say/ ID - ref1 ER - TY - STD TI - Yin C, Jing M: Baidu ordered to overhaul its healthcare ads. In China Daily http://europe.chinadaily.com.cn/business/2016-05/10/content_25191508_2.htm. Accessed 10 Jan 2017. UR - http://europe.chinadaily.com.cn/business/2016-05/10/content_25191508_2.htm ID - ref2 ER - TY - JOUR AU - Wang, J. B. AU - Guo, J. J. AU - Yang, L. AU - Zhang, Y. D. AU - Sun, Z. Q. AU - Zhang, Y. J. PY - 2010 DA - 2010// TI - Rare diseases and legislation in China JO - Lancet VL - 375 UR - https://doi.org/10.1016/S0140-6736(10)60240-1 DO - 10.1016/S0140-6736(10)60240-1 ID - Wang2010 ER - TY - STD TI - RARE diseases: Facts and statistics. Global Genes. https://globalgenes.org/rare-diseases-facts-statistics/. Accessed 10 Jan 2017. UR - https://globalgenes.org/rare-diseases-facts-statistics/ ID - ref4 ER - TY - STD TI - Evaluate Ltd. Orphan drug report 2014. London: Evaluate Ltd.; 2014. ID - ref5 ER - TY - JOUR AU - Gong, S. AU - Wang, Y. AU - Pan, X. AU - Zhang, L. AU - Huang, R. AU - Chen, X. AU - Hu, J. AU - Xu, Y. AU - Jin, S. PY - 2016 DA - 2016// TI - The availability and affordability of orphan drugs for rare diseases in China JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0392-4 DO - 10.1186/s13023-016-0392-4 ID - Gong2016 ER - TY - STD TI - Thomas MT. The Orphan Drug Act and the development of products for rare diseases. US Food and Drug Administration. https://rarediseases.info.nih.gov/files/FDA%20Orphan%20drugs.pdf. Accessed 10 Jan 2017. UR - https://rarediseases.info.nih.gov/files/FDA%20Orphan%20drugs.pdf ID - ref7 ER - TY - STD TI - Food and Drug Administration modernization act of 1997. In: S830, 105th Congress edition; Became law November 21; 1997. ID - ref8 ER - TY - CHAP AU - Ramsey, L. PY - 2015 DA - 2015// TI - The CEO who jacked up the price of a drug by 5,000% has done this before BT - Business Insider ID - Ramsey2015 ER - TY - CHAP AU - Mclean, B. PY - 2016 DA - 2016// TI - The Valeant meltdown and Wall Street’s major drug problem BT - Vanity Fair ID - Mclean2016 ER - TY - JOUR AU - Côté, A. AU - Keating, B. PY - 2012 DA - 2012// TI - What is wrong with orphan drug policies? JO - Value Health VL - 15 UR - https://doi.org/10.1016/j.jval.2012.09.004 DO - 10.1016/j.jval.2012.09.004 ID - Côté2012 ER - TY - JOUR AU - Gong, S. AU - Jin, S. PY - 2012 DA - 2012// TI - Current progress in the management of rare diseases and orphan drugs in China JO - Intractable Rare Dis Res VL - 1 ID - Gong2012 ER - TY - CHAP AU - Qian, Z. PY - 2015 DA - 2015// TI - Trying to create a family of ‘orphan drugs’ BT - Shanghai Daily ID - Qian2015 ER - TY - JOUR AU - Rawlins, M. D. AU - Culyer, A. J. PY - 2004 DA - 2004// TI - National Institute for Clinical Excellence and its value judgments JO - BMJ VL - 329 UR - https://doi.org/10.1136/bmj.329.7459.224 DO - 10.1136/bmj.329.7459.224 ID - Rawlins2004 ER - TY - JOUR AU - Drummond, M. F. PY - 2008 DA - 2008// TI - Challenges in the economic evaluation of orphan drugs JO - Eurohealth VL - 14 ID - Drummond2008 ER - TY - STD TI - Pacific Bridge Medical. Orphan drugs in Asia 2014: Guidelines and regulatory requirements to help orphan drug products enter the Asian market. Bethesda: Pacific Bridge Medical; 2014. ID - ref16 ER - TY - JOUR AU - Gao, J. J. AU - Song, P. P. AU - Tang, W. PY - 2013 DA - 2013// TI - Rare disease patients in China anticipate the sunlight of legislation JO - Drug Discov Ther VL - 7 ID - Gao2013 ER - TY - JOUR AU - Drummond, M. F. AU - Wilson, D. A. AU - Kanavos, P. AU - Ubel, P. AU - Rovira, J. PY - 2007 DA - 2007// TI - Assessing the economic challenges posed by orphan drugs JO - Int J Technol Assess Health Care VL - 23 UR - https://doi.org/10.1017/S0266462307051550 DO - 10.1017/S0266462307051550 ID - Drummond2007 ER - TY - STD TI - Bemus P. Building an alternative distribution model for ultra-orphan diseases. Pharm Commerce. 2009. ID - ref19 ER - TY - JOUR AU - Cuffe, R. L. AU - Lawrence, D. AU - Stone, A. AU - Vandemeulebroecke, M. PY - 2014 DA - 2014// TI - When is a seamless study desirable? Case studies from different pharmaceutical sponsors JO - Pharm Stat VL - 13 UR - https://doi.org/10.1002/pst.1622 DO - 10.1002/pst.1622 ID - Cuffe2014 ER - TY - JOUR AU - Alemayehu, D. AU - Levenstein, M. AU - Knirsch, C. PY - 2014 DA - 2014// TI - Statistical considerations for clinical trials in rare diseases JO - J Rare Disord VL - 2 ID - Alemayehu2014 ER - TY - JOUR AU - Cornu, C. AU - Kassai, B. AU - Fisch, R. AU - Chiron, C. AU - Alberti, C. AU - Guerrini, R. AU - Rosati, A. AU - Pons, G. AU - Tiddens, H. AU - Chabaud, S. PY - 2013 DA - 2013// TI - Experimental designs for small randomised clinical trials: an algorithm for choice JO - Orphanet J Rare Dis VL - 8 UR - https://doi.org/10.1186/1750-1172-8-48 DO - 10.1186/1750-1172-8-48 ID - Cornu2013 ER - TY - JOUR AU - Mullard, A. PY - 2015 DA - 2015// TI - FDA approves ultra-orphan drug on a 4-patient trial JO - Nat Rev Drug Discov VL - 14 ID - Mullard2015 ER - TY - JOUR AU - Alexander, W. PY - 2013 DA - 2013// TI - The uphill path to successful clinical trials: Keeping patients enrolled JO - Pharm Ther VL - 38 ID - Alexander2013 ER - TY - JOUR AU - Morel, T. AU - Aymé, S. AU - Cassiman, D. AU - Simoens, S. AU - Morgan, M. AU - Vandebroek, M. PY - 2016 DA - 2016// TI - Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0444-9 DO - 10.1186/s13023-016-0444-9 ID - Morel2016 ER - TY - STD TI - Rare diseases: common issues in drug development. Draft guidance. US Food and Drug Administration; 2015. ID - ref26 ER - TY - JOUR AU - Song, P. AU - Gao, J. AU - Inagaki, Y. AU - Kokudo, N. AU - Tang, W. PY - 2012 DA - 2012// TI - Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives JO - Intractable Rare Dis Res VL - 1 ID - Song2012 ER - TY - JOUR AU - Zhong, Y. -. Q. AU - Fu, J. -. J. AU - Liu, X. -. M. AU - Diao, X. AU - Mao, B. AU - Fan, T. AU - Yang, H. -. M. AU - Liu, G. -. J. AU - Zhang, W. -. B. PY - 2010 DA - 2010// TI - The reporting quality, scientific rigor, and ethics of randomized placebo-controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials JO - Curr Ther Res VL - 71 UR - https://doi.org/10.1016/j.curtheres.2010.02.001 DO - 10.1016/j.curtheres.2010.02.001 ID - Zhong2010 ER - TY - JOUR AU - Colquhoun, D. AU - Novella, S. P. PY - 2013 DA - 2013// TI - Acupuncture is theatrical placebo JO - Anesth Analg VL - 116 UR - https://doi.org/10.1213/ANE.0b013e31828f2d5e DO - 10.1213/ANE.0b013e31828f2d5e ID - Colquhoun2013 ER - TY - JOUR AU - Tuttle, A. H. AU - Tohyama, S. AU - Ramsay, T. AU - Kimmelman, J. AU - Schweinhardt, P. AU - Bennett, G. J. AU - Mogil, J. S. PY - 2015 DA - 2015// TI - Increasing placebo responses over time in U.S. clinical trials of neuropathic pain JO - Pain VL - 156 UR - https://doi.org/10.1097/j.pain.0000000000000333 DO - 10.1097/j.pain.0000000000000333 ID - Tuttle2015 ER - TY - JOUR AU - Waber, R. L. AU - Shiv, B. AU - Carmon, Z. AU - Ariely, D. PY - 2008 DA - 2008// TI - Commercial features of placebo and therapeutic efficacy JO - JAMA VL - 299 UR - https://doi.org/10.1001/jama.299.9.1016 DO - 10.1001/jama.299.9.1016 ID - Waber2008 ER - TY - JOUR AU - Phillips, D. P. AU - Ruth, T. E. AU - Wagner, L. M. PY - 1993 DA - 1993// TI - Psychology and survival JO - Lancet VL - 342 UR - https://doi.org/10.1016/0140-6736(93)92124-C DO - 10.1016/0140-6736(93)92124-C ID - Phillips1993 ER - TY - JOUR AU - Cui, Y. AU - Zhao, H. AU - Liu, Z. AU - Liu, C. AU - Luan, J. AU - Zhou, X. AU - Han, J. PY - 2012 DA - 2012// TI - A systematic review of genetic skeletal disorders reported in Chinese biomedical journals between 1978 and 2012 JO - Orphanet J Rare Dis VL - 7 UR - https://doi.org/10.1186/1750-1172-7-55 DO - 10.1186/1750-1172-7-55 ID - Cui2012 ER - TY - JOUR AU - Cui, Y. AU - Han, J. PY - 2015 DA - 2015// TI - A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs JO - Orphanet J Rare Dis VL - 10 UR - https://doi.org/10.1186/s13023-015-0241-x DO - 10.1186/s13023-015-0241-x ID - Cui2015 ER - TY - JOUR AU - Cui, Y. AU - Zhou, X. AU - Han, J. PY - 2014 DA - 2014// TI - China launched a pilot project to improve its rare disease healthcare levels JO - Orphanet J Rare Dis VL - 9 UR - https://doi.org/10.1186/1750-1172-9-14 DO - 10.1186/1750-1172-9-14 ID - Cui2014 ER - TY - JOUR AU - Schuller, Y. AU - Hollak, C. E. M. AU - Biegstraaten, M. PY - 2015 DA - 2015// TI - The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review JO - Orphanet J Rare Dis VL - 10 UR - https://doi.org/10.1186/s13023-015-0305-y DO - 10.1186/s13023-015-0305-y ID - Schuller2015 ER - TY - STD TI - Unlocking lifesaving treatments for rare-diseases act, H.R. 3737, 112th Congress. (2011-2012). ID - ref37 ER - TY - JOUR AU - Inagaki, Y. AU - Song, P. PY - 2013 DA - 2013// TI - Necessity of cooperation with government on publication of scientific research results for intractable diseases JO - Intractable Rare Dis Res VL - 2 ID - Inagaki2013 ER - TY - JOUR AU - Pinto, D. AU - Martin, D. AU - Chenhall, R. PY - 2016 DA - 2016// TI - The involvement of patient organisations in rare disease research: a mixed methods study in Australia JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0382-6 DO - 10.1186/s13023-016-0382-6 ID - Pinto2016 ER - TY - STD TI - Comradis Limited. Rare diseases in China: rising to meet the challenge. London; 2016. ID - ref40 ER - TY - JOUR AU - Tang, W. PY - 2013 DA - 2013// TI - Hopes for intractable and rare diseases research JO - Intractable Rare Dis Res VL - 2 ID - Tang2013 ER - TY - JOUR AU - Liu, X. AU - Cui, Y. AU - Li, Y. AU - Wang, C. AU - Zhao, H. AU - Han, J. PY - 2016 DA - 2016// TI - Using inpatient data to estimate the prevalence of Wegener’s granulomatosis in China JO - Intractable Rare Dis Res VL - 5 UR - https://doi.org/10.5582/irdr.2015.01015 DO - 10.5582/irdr.2015.01015 ID - Liu2016 ER - TY - JOUR AU - Sharma, A. AU - Jacob, A. AU - Tandon, M. AU - Kumar, D. PY - 2010 DA - 2010// TI - Orphan drug: Development trends and strategies JO - J Pharm Bioallied Sci VL - 2 UR - https://doi.org/10.4103/0975-7406.72128 DO - 10.4103/0975-7406.72128 ID - Sharma2010 ER - TY - STD TI - Regulatory framework for drugs for rare diseases. In: Field M, Boat T, editors. Rare diseases and orphan products: accelerating research and development. Washington: National Academies Press; 2010. ID - ref44 ER - TY - STD TI - US Food and Drug Administration. Developing products for rare diseases & conditions. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ucm2005525.htm. Accessed 10 Jan 2017. UR - http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ucm2005525.htm ID - ref45 ER - TY - STD TI - Orphan drug designations and approvals. US Food and Drug Administration Orphan Drug Product designation database. Search period January 1, 1983 to June 14, 2016. ID - ref46 ER - TY - JOUR AU - Silva, E. N. AU - Sousa, T. R. V. PY - 2015 DA - 2015// TI - Economic evaluation in the context of rare diseases: is it possible? JO - Cadernos de Saúde Pública VL - 31 UR - https://doi.org/10.1590/0102-311X00213813 DO - 10.1590/0102-311X00213813 ID - Silva2015 ER - TY - STD TI - Guideline on the procedure for accelerated assessment pursuant to article 14 (9) of regulation (EC) No 726/2004. In: EMEA/419127/05 (Agency EM ed. London, UK; July 17; 2006. ID - ref48 ER - TY - STD TI - European Commission of Public Health. Register of designated orphan medicinal products. http://ec.europa.eu/health/documents/community-register/html/orphreg.htm. Accessed 10 Jan 2017. UR - http://ec.europa.eu/health/documents/community-register/html/orphreg.htm ID - ref49 ER -